Although cytogenetic responses had originally been the gold standard to assess treatment response in CML patients, BCR-ABL1 transcript level by quantitative PCR assays (RQ-PCR) has become the reference in the last two decades and international collaboration has allowed harmonization of protocol and reporting of results [9]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.